02 Aug 2010
Shire Appoints Gráinne Higgins Global Vice President of Human Resources for Human Genetic Therapies Business
Nyon, Switzerland and Lexington, MA, US – August 2, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that Gráinne Higgins has been appointed Global Vice President of Human Resources for its Human Genetic Therapies (HGT) business. Ms. Higgins will report directly to Ann Judge, Senior Vice President Global Human Resources. As part of the HGT leadership team, Ms. Higgins will be responsible for driving people initiatives in support of HGT’s global business strategy partnering closely with Sylvie Grégoire, PharmD, President of Shire Human Genetic Therapies.
Ms. Higgins brings over 20 years of human resources experience to Shire. She was most recently the Regional Human Resources Lead for Merck & Co in Lucerne, Switzerland, where she managed all human resources activities for 31 countries across Europe. Prior to the merger of Merck and Schering-Plough, Ms. Higgins was Vice President of Human Resources for Schering-Plough, Global Animal Health. Higgins joined Schering-Plough in 1997 following the acquisition of Mallinckrodt Veterinary and subsequently moved to New Jersey, where she held various positions of increasing responsibility. Before returning to Europe in 2007, Ms. Higgins led the pre-planning of the integration of Organon BioSciences into Schering Plough.
Ms. Higgins earned an M.S. degree in organization behavior from Trinity College in Dublin as well as a national diploma in personnel management from the National College of Industrial Relations. She graduated with honors from University College Dublin, where she earned a bachelor of social science degree. She was awarded the Tribute to Women in Industry Award in New Jersey in 2003.
"We are pleased to have Gráinne join Shire’s team and to build upon our organizational capabilities to enable achievement of our business strategies” says Ann Judge, Head of Shire Global Human Resources. ”As the HGT business continues to expand, Gráinne’s breadth of experience will undoubtedly play an integral role in our ability to cultivate the human capital that enables our growth as an organization."
For further information please contact:
Jessica Mann (Rest of the World)
+44 1256 894 280
Jessica Cotrone (North America, HGT)
+1 781 482 9538
Notes to editors
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.